LSD Microdosing: The Science

Few corners of the psychedelic world are as hyped — or as hard to pin down — as microdosing. Silicon Valley swears by it; wellness influencers sell protocols for it; and millions of people are convinced a crumb of LSD every few days has changed their lives. The science is more sobering, and more interesting, than either the believers or the debunkers let on. This article is education, not medical advice, and its whole value is in telling the honest version.

We’ve mapped the 5-HT2A receptor that full-dose psychedelics act on, and compared psilocybin and LSD head to head. Microdosing is the low-dose frontier of that same molecule — and the place where separating real pharmacology from wishful thinking matters most. Here’s what the controlled evidence actually shows. (Educational overview only.)

What microdosing actually is

A microdose is a sub-perceptual dose — small enough that you shouldn’t feel obviously “high,” but, the theory goes, large enough to nudge mood, focus or creativity. For LSD that’s roughly 5 to 20 micrograms, about one-tenth of a typical recreational dose of ~100 µg. The modern practice was popularized by psychologist James Fadiman in his 2011 book The Psychedelic Explorer’s Guide, and the best-known schedule bears his name: the Fadiman protocol — one dosing day followed by two days off, repeated for a few weeks and then paused. The two off-days are meant to let effects “integrate” and to blunt the rapid tolerance LSD builds. It’s worth being clear that this is a folk protocol refined through anecdote and survey data, not a schedule validated by dose-finding trials.

The placebo problem — the heart of the matter

Here is the crux of the whole topic. When you ask people who microdose whether it works, the answer is overwhelmingly yes. But belief is a confound, not evidence — and microdosing is almost impossible to blind, because devotees often know what a real dose feels like. So a team led by Balázs Szigeti designed something clever: a self-blinding citizen-science study. Participants followed instructions to prepare their own capsules — some with a real microdose, some empty placebo — sealed inside QR-coded envelopes, so that they, and the researchers, were blinded to which was which until the end.

The result is the single most important finding in the field. Across roughly 190 completers, psychological measures — wellbeing, mood, life satisfaction — improved significantly over the study. But they improved in both the microdose and the placebo groups, with no significant difference between them on the main outcomes. In other words, people got better whether they took LSD or a sugar-filled capsule — as long as they believed they might be microdosing (Szigeti et al., eLife 2021). A 2023 reanalysis went further, showing how easily broken blinding and activated expectancy can manufacture a false drug signal in naturalistic studies (Szigeti et al., Scientific Reports 2023). The honest headline: much of what people attribute to the drug appears to be the placebo effect — which is powerful and real, but not pharmacology.

What the controlled lab studies show

That doesn’t mean low-dose LSD does nothing. In tightly controlled laboratory studies — where doses are exact and blinding holds — a clearer, more modest picture emerges. Harriet de Wit’s group at Chicago gave healthy volunteers placebo, 6.5, 13 or 26 µg of LSD across separate sessions. The effects were dose-related but small: at the highest dose people felt more vigor and elation — but also more anxiety, with little change to cognition or most physiological measures (Bershad et al., Biological Psychiatry 2019). Notably, the effects at genuine microdose levels weren’t uniformly “positive.”

Then came the cleaner test: a repeated-dose randomized trial. The same group had 80 healthy volunteers take either 10 µg LSD or placebo every three days for six weeks, mostly at home. LSD produced transient mood lifts on dosing days — but no lasting change to overall mood or cognition, and treatment-related anxiety was the most common adverse event (de Wit et al., Biological Psychiatry 2023). This is one of the sharpest results in the whole literature: a real acute pharmacological blip that simply doesn’t add up to durable benefit.

Felt versus measured

One of the most consistent patterns in microdosing research is a gap between what people feel and what instruments measure. Subjective ratings of creativity, focus and wellbeing rise; objective performance on creativity and cognition tasks usually doesn’t budge. Across the experimental creativity studies, only a minority found any objective improvement, while self-rated creativity climbed. In self-blinding data, the subjective effects tracked whether people believed they’d taken a real dose — not what they’d actually swallowed. The likely explanation is an inflated sense of meaning and insight rather than a genuine boost in performance. It’s a humbling reminder that feeling more creative and being more creative are not the same measurement.

The real pharmacology of a sliver of LSD

So is it all placebo? No — and saying so would overstate the case. Under rigorous control, acute microdoses of LSD dose-dependently alter blood pressure, sleep, neural connectivity, time perception, and the perception of pain, with a perceptual threshold that sits around 10–20 µg and essentially nothing at 5 (Murphy, Muthukumaraswamy & de Wit, Biol Psychiatry CNNI 2024). Low doses measurably change the EEG, reducing certain oscillatory rhythms even when behavioural effects are minimal — the brain clearly notices. And in one striking study, 20 µg of LSD increased tolerance to cold-pressor pain to a degree the authors compared to opioids — though only at 20 µg, where mild psychoactivity begins, and a 2025 replication at 15 µg failed to find the effect in the full sample (Ramaekers et al., J Psychopharmacol 2021). The signal is real, dose-dependent, and fragile — exactly the kind of thing that gets lost in the hype.

Safety — and one honest question mark

In the short term, low-dose LSD looks well tolerated. A study in 48 healthy older adults given up to 20 µg six times over three weeks found adverse events no more frequent than placebo, and no impairment of cognition, balance or proprioception (Family et al., Psychopharmacology 2020). But short-term tolerability says nothing about years of use, and there is one mechanistic worry that deserves to be stated plainly. LSD binds not only 5-HT2A but also the 5-HT2B receptor — and chronic, strong 5-HT2B activation is the mechanism behind heart-valve disease, the same pathway that led to the withdrawal of the diet drug combination fen-phen. Because microdosing means frequent, repeated dosing over months or years, researchers have flagged a theoretical risk of valvulopathy (Tagen et al., J Psychopharmacol 2023). It has not been demonstrated in humans, and early animal data are somewhat reassuring — but there are essentially no long-term human safety data, and LSD remains illegal (Schedule I) in the US and most countries. The honest status is: plausible, unresolved, uncharacterized.

Don’t confuse it with the LSD in the headlines

One clarification worth making, because the two are constantly conflated: the recent clinical successes for LSD are not microdosing. A 2024 Phase 2 trial of a pharmaceutical LSD formulation (MM120) for generalized anxiety used a single full dose (~100 µg) with psychological support and reported meaningful, durable reductions in anxiety, earning FDA Breakthrough Therapy designation (Phase 2b GAD trial, JAMA Psychiatry 2024). That is the opposite of frequent sub-perceptual dosing — a full therapeutic experience, once. When you see “LSD shows promise” in the news, it’s almost always the full-dose, supported model, not the crumb-every-third-day one.

The honest bottom line

Here is where the evidence stands as of 2026, stated evenhandedly. First: the best-controlled research suggests that most of the wellbeing, mood and creativity benefit people report from microdosing is expectancy-driven — the self-blinding study and the repeated-dose trials are the strongest evidence, and they point that way. Second: low-dose LSD is nonetheless genuinely pharmacologically active, shifting blood pressure, brain rhythms, time perception and pain in measurable, dose-dependent ways; “it’s all placebo” is as wrong as “it’s a miracle.” Third: the durable clinical benefits people hope for remain largely unproven, and long-term safety — especially the heart-valve question — is uncharacterized. The most accurate summary is unglamorous but true: microdosing does real, modest, mostly acute things, a great deal of the felt benefit is the placebo effect doing honest work, and the big claims are still waiting on the big trials.

OOTW Journal is educational and does not provide medical advice. LSD is a Schedule I controlled substance in the United States and is illegal in most countries; the studies described here were conducted in regulated research settings. There is a theoretical, unresolved long-term cardiac risk to frequent dosing, and no long-term human safety data exist. Nothing here is a recommendation to seek or use LSD. If you are struggling with your mental health, please reach out to a qualified professional. This article is education, not medical advice.